Program of Angiotensin-Neprilysin Inhibition in Admitted Patients With Worsening Heart Failure (PREMIER)

PHASE4Active, not recruitingINTERVENTIONAL
Enrollment

400

Participants

Timeline

Start Date

December 27, 2021

Primary Completion Date

February 8, 2024

Study Completion Date

March 31, 2025

Conditions
Heart Failure
Interventions
DRUG

Sacubitril Valsartan Sodium Hydrate

"Switch from the ACE inhibitor or ARB that was taken before the allocation, and start oral administration twice daily with a starting dose of 50 mg of sacubitril valsartan. The duration of administration of the ACE inhibitor or ARB before allocation does not matter, but when switching from the ACE inhibitor, administration of sacubitril valsartan should be started at least 36 hours after the final administration of the drug.~After the start of administration, the dose is gradually increased to 100 mg and 200 mg once at intervals of 2 to 4 weeks, referring to the latest package insert and safety and tolerability standards. At that time, if the doctor in charge determines that the dose is not tolerated after the dose is increased, the dose may be reduced to the previous dose or the drug may be suspended depending on the medical situation."

DRUG

Standard treatment

Standard treatment, other than Sacubitril Valsartan Sodium Hydrate, for HF

Trial Locations (1)

849-8501

Saga University Hospital, Saga

All Listed Sponsors
lead

Saga University

OTHER

NCT05164653 - Program of Angiotensin-Neprilysin Inhibition in Admitted Patients With Worsening Heart Failure (PREMIER) | Biotech Hunter | Biotech Hunter